<VariationArchive VariationID="2786411" VariationName="NM_000098.3(CPT2):c.1613del (p.Tyr538fs)" VariationType="Deletion" Accession="VCV002786411" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-29" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2938916" VariationID="2786411">
      <GeneList>
        <Gene Symbol="CPT2" FullName="carnitine palmitoyltransferase 2" GeneID="1376" HGNC_ID="HGNC:2330" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p32.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="53196824" stop="53214197" display_start="53196824" display_stop="53214197" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="53662100" stop="53679868" display_start="53662100" display_stop="53679868" Strand="+" />
          </Location>
          <OMIM>600650</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000098.3(CPT2):c.1613del (p.Tyr538fs)</Name>
      <CanonicalSPDI>NC_000001.11:53211286:A:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p32.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="53211287" stop="53211287" display_start="53211287" display_stop="53211287" variantLength="1" positionVCF="53211286" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="53676959" stop="53676959" display_start="53676959" display_stop="53676959" variantLength="1" positionVCF="53676958" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>Y538fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.53676959del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.53676959del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.53211287del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.53211287del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008035.1" sequenceAccession="NG_008035" sequenceVersion="1" change="g.19859del">
            <Expression>NG_008035.1:g.19859del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000098.3" sequenceAccession="NM_000098" sequenceVersion="3" change="c.1613del" MANESelect="true">
            <Expression>NM_000098.3:c.1613del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000089.1" sequenceAccession="NP_000089" sequenceVersion="1" change="p.Tyr538fs">
            <Expression>NP_000089.1:p.Tyr538fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330589.2" sequenceAccession="NM_001330589" sequenceVersion="2" change="c.1576+37del">
            <Expression>NM_001330589.2:c.1576+37del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000098.3(CPT2):c.1613del (p.Tyr538fs) AND Carnitine palmitoyltransferase II deficiency" Accession="RCV003741449" Version="1">
        <ClassifiedConditionList TraitSetID="10067">
          <ClassifiedCondition DB="MedGen" ID="C0342790">Carnitine palmitoyltransferase II deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-22" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17936304</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21913903</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="10067" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6221" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyl transferase 2 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyltransferase II deficiency</ElementValue>
                <XRef ID="MONDO:0015515" DB="MONDO" />
                <XRef ID="238002005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase deficiency type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CPT2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1121" />
                <XRef ID="1121" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="157" DB="Orphanet" />
              <XRef ID="C0342790" DB="MedGen" />
              <XRef ID="MONDO:0015515" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8170335" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="16247190|MedGen:C0342790" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004381578" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17936304</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21913903</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Tyr538Serfs*5) in the CPT2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 121 amino acid(s) of the CPT2 protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CPT2-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the CPT2 protein in which other variant(s) (p.Glu645Argfs*5) have been determined to be pathogenic (PMID: 17936304, 21913903). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.53676959del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0342790" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8170335" TraitType="Disease" MappingType="XRef" MappingValue="C0342790" MappingRef="MedGen">
        <MedGen CUI="C0342790" Name="Carnitine palmitoyltransferase II deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

